Dyadic International (NASDAQ:DYAI) Stock Crosses Below 50 Day Moving Average – Here’s What Happened

Dyadic International Inc. (NASDAQ:DYAI)’s share price passed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $0.88 and traded as low as $0.7802. Dyadic International shares last traded at $0.7802, with a volume of 41,670 shares changing hands.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dyadic International in a research note on Monday, December 29th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $3.00.

Dyadic International Stock Down 0.2%

The business has a 50-day moving average price of $0.88 and a 200 day moving average price of $0.95. The company has a current ratio of 2.85, a quick ratio of 2.85 and a debt-to-equity ratio of 1.92. The stock has a market capitalization of $28.19 million, a P/E ratio of -3.25 and a beta of 1.27.

Institutional Trading of Dyadic International

Large investors have recently made changes to their positions in the business. Apis Capital Advisors LLC bought a new position in shares of Dyadic International in the 3rd quarter valued at about $1,817,000. Perkins Capital Management Inc. lifted its stake in shares of Dyadic International by 627.4% in the 3rd quarter. Perkins Capital Management Inc. now owns 348,050 shares of the biotechnology company’s stock valued at $411,000 after purchasing an additional 300,200 shares during the last quarter. Landscape Capital Management L.L.C. purchased a new position in shares of Dyadic International in the 3rd quarter worth approximately $190,000. Truist Financial Corp increased its position in shares of Dyadic International by 30.5% during the 3rd quarter. Truist Financial Corp now owns 326,200 shares of the biotechnology company’s stock valued at $385,000 after purchasing an additional 76,200 shares during the last quarter. Finally, AlphaCore Capital LLC purchased a new stake in Dyadic International during the 2nd quarter valued at $50,000. 27.95% of the stock is currently owned by institutional investors.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.